Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

類似資料

• Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
  著者:: Raschi, Emanuel, 等
  出版事項: (2020)
• Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
  著者:: Raschi, Emanuel, 等
  出版事項: (2020)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  著者:: Raschi, Emanuel, 等
  出版事項: (2019)
• Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
  著者:: Raschi, Emanuel, 等
  出版事項: (2019)
• Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
  著者:: Poluzzi, Elisabetta, 等
  出版事項: (2013)